FORA Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

FORA Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57M	Buy	5,209 +738	+17%	+$223K	0.11%	179
2026 Q1	$1.48M	Buy	4,471 +1,005	+29%	+$342K	0.11%	193
2025 Q4	$1.38M	Buy	3,466 +747	+27%	+$331K	0.17%	160
2025 Q3	$1.24M	Buy	+2,719	New	+$1.11M	0.22%	124
2025 Q2	–	Sell	-8,624	Closed	-$2.33M	–	493
2025 Q1	$2.33M	Sell	8,624 -4,074	-32%	-$1.05M	0.24%	137
2024 Q4	$2.99M	Buy	+12,698	New	+$3.34M	0.34%	94
2024 Q3	–	Sell	-7,173	Closed	-$1.74M	–	429
2024 Q2	$1.74M	Buy	+7,173	New	+$1.13M	0.21%	154
2024 Q1	–	Sell	-1,705	Closed	-$326K	–	398
2023 Q4	$326K	Buy	+1,705	New	+$290K	0.03%	382
2022 Q4	–	Sell	-8,774	Closed	-$1.76M	–	452
2022 Q3	$1.76M	Buy	+8,774	New	+$1.67M	0.34%	87
2021 Q4	–	Sell	-2,229	Closed	-$421K	–	301
2021 Q3	$421K	Sell	2,229 -435	-16%	-$81.6K	0.11%	230
2021 Q2	$452K	Buy	+2,664	New	+$390K	0.08%	282
2020 Q3	–	Sell	-7,026	Closed	-$1.04M	–	639
2020 Q2	$1.04M	Buy	+7,026	New	+$947K	0.36%	62
2020 Q1	–	Sell	-10,529	Closed	-$1.21M	–	1015
2019 Q4	$1.21M	Buy	+10,529	New	+$1.05M	0.12%	221

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FORA Capital's ALNY Position: Q2 2026 in Review

FORA Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 17% in Q2 2026, buying an estimated $223K and bringing the position to 5,209 shares worth $1.57M. The position accounts for 0.11% of the portfolio, ranked #179.

FORA Capital first reported a position in ALNY in Q4 2019 and has held it in 13 quarters since. The position peaked at $2.99M in Q4 2024. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

FORA Capital held 5,209 shares of Alnylam Pharmaceuticals worth $1.57M as of Q2 2026.
FORA Capital bought 738 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $223K.
Alnylam Pharmaceuticals made up 0.11% of FORA Capital's portfolio in Q2 2026, its #179 holding.
FORA Capital first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 13 quarters since.
FORA Capital's Alnylam Pharmaceuticals position peaked at $2.99M in Q4 2024.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.